Onderneming Iovance Biotherapeutics Inc Nasdaq
Aandelen
US53619R1023
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Autologous Tumor Infiltrating Lymphocytes
100,0
%
| 0 | nan % | 1 | 100,0 % | - |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 0 | nan % | 1 | 100,0 % | - |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Frederick Vogt
CEO | Chief Executive Officer | 50 | 30-09-16 |
Director of Finance/CFO | 51 | 14-12-20 | |
Brian Shew
CTO | Chief Tech/Sci/R&D Officer | - | 01-07-21 |
Chief Tech/Sci/R&D Officer | 51 | 18-07-19 | |
Igor Bilinsky
COO | Chief Operating Officer | 51 | 15-03-21 |
Merrill McPeak
BRD | Director/Board Member | 88 | 20-07-11 |
Sara Pellegrino
IRC | Investor Relations Contact | - | - |
Tracy Winton
HRO | Human Resources Officer | - | 01-04-20 |
Raj K. Puri
PRN | Corporate Officer/Principal | - | 01-03-22 |
Jim Ziegler
PRN | Corporate Officer/Principal | - | 01-02-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Merrill McPeak
BRD | Director/Board Member | 88 | 20-07-11 |
Director/Board Member | 56 | 07-06-16 | |
Michael Weiser
BRD | Director/Board Member | 61 | 15-03-18 |
Wendy Yarno
BRD | Director/Board Member | 69 | 18-04-23 |
Ryan Maynard
BRD | Director/Board Member | 54 | 16-02-15 |
Iain Dukes
CHM | Chairman | 65 | 01-06-16 |
Director/Board Member | 52 | 10-06-19 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 2 842 158 | 0 | 0 | 92,59 % |
Aandeel B | 0 | 194 | 0 | 0 | |
Aandeel C | 1 | 279 832 722 | 259 105 707 ( 92,59 %) | 0 |
Bedrijfsgegevens
Iovance Biotherapeutics, Inc.
825 Industrial Road Suite 400
94070, San Carlos
+650 260 7120
http://www.iovance.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
-28,50% | 9,84 mld. | |
+0,15% | 3,15 mld. | |
-14,73% | 2,15 mld. | |
-13,23% | 1,8 mld. | |
+72,37% | 1,49 mld. | |
+23,83% | 770 mln. | |
-2,84% | 762 mln. | |
-22,86% | 575 mln. | |
+5,37% | 308 mln. |